Gold bars to be exempt from tariffs, White House clarifies
Chemed Corp (NYSE:CHE)’s stock reached a new 52-week low, closing at 410.0 USD. According to InvestingPro data, the company maintains strong financial health with an overall score of "GREAT" and has been actively managing capital through share buybacks. This milestone comes amidst a challenging year for the company, as reflected in its 1-year change data, which shows a decline of 26.83%. Despite the downturn, the company maintains solid fundamentals with a healthy current ratio of 1.73 and moderate debt levels. The company has also demonstrated commitment to shareholder returns, having maintained dividend payments for 55 consecutive years. This context highlights the complex dynamics currently impacting the healthcare sector. Investors are closely monitoring the company’s performance and strategic responses as it navigates these challenges. Based on current metrics, InvestingPro analysis indicates the stock may be undervalued. For deeper insights into Chemed’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Chemed Corporation reported second-quarter earnings that fell short of analyst expectations. The company announced adjusted earnings per share of $4.27 for the quarter ending June 30, 2025, which was below the analyst estimate of $5.39. Revenue for the quarter was $618.8 million, showing a 3.8% increase year-over-year but still missing the consensus estimate of $650.6 million. Additionally, Chemed has revised its full-year outlook downward, which has raised concerns among investors. The company operates VITAS Healthcare and Roto-Rooter, and the disappointing earnings have sparked a reevaluation of its financial projections. These recent developments have caught the attention of various analyst firms. While the company did not meet expectations, the revenue growth indicates some positive trends. The revised guidance is a key factor that analysts and investors will continue to monitor closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.